Advanced non-small cell lung cancer therapy: historical and future perspectives

By Reck M.  

Targeted Oncology, Vol. 3, Iss. 3, 2008-07 ,pp. : 135-147

Springer Publishing Company

Access to resources Recommend Favorite

Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients

By Park So-Yeon   Hong Yun-Chul   Kim Jin-Hee   Kwak Seung-Min   Cho Jae-Hwa   Lee Hong-Lyeol   Ryu Jeong-Seon  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 489-498

Humana Press, Inc

Access to resources Recommend Favorite

PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells

By Cheng Haiying  

Carcinogenesis, Vol. 34, Iss. 4, 2013-04 ,pp. : 739-749

Oxford University Press

Access to resources Recommend Favorite

Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis

By Wei Shu-zhen  

Medical Oncology, Vol. 28, Iss. 1, 2011-03 ,pp. : 315-321

Humana Press, Inc

Access to resources Recommend Favorite

Prognostic significance of the mRNA expression of ERCC1, RRM1, TUBB3 and TYMS genes in patients with non-small cell lung cancer

By            

Experimental and Therapeutic Medicine, Vol. 10, Iss. 3, 2015-01 ,pp. : 937-941

Spandidos Publications

Access to resources Recommend Favorite